Human lung-derived mesenchymal stem cell-conditioned medium exerts in vitro antitumor effects in malignant pleural mesothelioma cell lines

被引:25
作者
Cortes-Dericks, Lourdes [1 ]
Froment, Laurene [1 ]
Kocher, Gregor [1 ]
Schmid, Ralph A. [1 ]
机构
[1] Univ Hosp Bern, Dept Clin Res, Div Gen Thorac Surg, CH-3010 Bern, Switzerland
关键词
Malignant pleural mesothelioma; Human lung mesenchymal stem cell-conditioned medium; Soluble factors; Sphere-forming cells; Cisplatin; BREAST-CANCER CELLS; STROMAL CELLS; TUMOR-GROWTH; DRUG-RESISTANCE; CARCINOMA; PROLIFERATION; MATRIX; VIVO; INHIBITION; EXPRESSION;
D O I
10.1186/s13287-016-0282-7
中图分类号
Q813 [细胞工程];
学科分类号
摘要
Background: The soluble factors secreted by mesenchymal stem cells are thought to either support or inhibit tumor growth. Herein, we investigated whether the human lung-derived mesenchymal stem cell-conditioned medium (hlMSC-CM) exerts antitumor activity in malignant pleural mesothelioma cell lines H28, H2052 and Meso4. Methods: hlMSC-CM was collected from the human lung-derived mesenchymal stem cells. Inhibition of tumor cell growth was based on the reduction of cell viability and inhibition of cell proliferation using the XTT and BrdU assays, respectively. Elimination of tumor spheroids was assessed by the anchorage-independent sphere formation assay. The cytokine profile of hlMSC-CM was determined by a chemiluminescence-based cytokine array. Results: Our data showed that hlMSC-CM contains a broad range of soluble factors which include: cytokines, chemokines, hormones, growth and angiogenic factors, matrix metalloproteinases, metalloproteinase inhibitors and cell-cell mediator proteins. The 48- and 72-hour hlMSC-CM treatments of H28, H2052 and Meso4 cell lines elicited significant decreases in cell viability and inhibited cell proliferation. The 72-hour hlMSC-CM incubation of H28 cells completely eliminated the drug-resistant sphere-forming cells, which is more potent than twice the half maximal inhibitory concentration of cisplatin. Conclusions: Our findings indicate that the cell-free hlMSC-CM confers in vitro antitumor activities via soluble factors in the tested mesothelioma cells and, hence, may serve as a therapeutic tool to augment the current treatment strategies in malignant pleural mesothelioma.
引用
收藏
页数:8
相关论文
共 36 条
[1]   Evolving role of uPA/uPAR system in human cancers [J].
Ass, Kathleen ;
Ahmad, Aamir ;
Azmi, Asfar S. ;
Sarkar, Sarah H. ;
Sarkar, Fazlul H. .
CANCER TREATMENT REVIEWS, 2008, 34 (02) :122-136
[2]   Naive human umbilical cord matrix derived stem cells significantly attenuate growth of human breast cancer cells in vitro and in vivo [J].
Ayuzawa, Rie ;
Doi, Chiyo ;
Rachakatla, Raja Shekar ;
Pyle, Marla M. ;
Maurya, Dharmendra Kumar ;
Troyer, Deryl ;
Tamura, Masaaki .
CANCER LETTERS, 2009, 280 (01) :31-37
[3]   Stem cell paracrine actions and tissue regeneration [J].
Baraniak, Priya R. ;
McDevitt, Todd C. .
REGENERATIVE MEDICINE, 2010, 5 (01) :121-143
[4]   TIMP-1 overexpression in pancreatic cancer attenuates tumor growth, decreases implantation and metastasis, and inhibits angiogenesis [J].
Bloomston, M ;
Shafii, S ;
Zervos, EE ;
Rosemurgy, AS .
JOURNAL OF SURGICAL RESEARCH, 2002, 102 (01) :39-44
[5]   Human mesenchymal stem cells and their paracrine factors for the treatment of brain tumors [J].
Chan, J. K. Y. ;
Lam, P. Y. P. .
CANCER GENE THERAPY, 2013, 20 (10) :539-543
[6]   Therapeutic Potential of Adult Bone Marrow-Derived Mesenchymal Stem Cells in Prostate Cancer Bone Metastasis [J].
Chanda, Diptiman ;
Isayeva, Tatyana ;
Kumar, Sanjay ;
Hensel, Jonathan A. ;
Sawant, Anandi ;
Ramaswamy, Girish ;
Siegal, Gene P. ;
Beatty, Matthew S. ;
Ponnazhagan, Selvarangan .
CLINICAL CANCER RESEARCH, 2009, 15 (23) :7175-7185
[7]   Hyperthermia-treated Mesenchymal Stem Cells Exert Antitumor Effects on Human Carcinoma Cell Line [J].
Cho, Jung Ah ;
Park, Ho ;
Kim, Hee Kyung ;
Lim, Eun Hye ;
Seo, Sang Won ;
Choi, Joong Sub ;
Lee, Kyo Won .
CANCER, 2009, 115 (02) :311-323
[8]   Cisplatin-resistant cells in malignant pleural mesothelioma cell lines show ALDHhighCD44+ phenotype and sphere-forming capacity [J].
Cortes-Dericks, Lourdes ;
Froment, Laurene ;
Boesch, Ruben ;
Schmid, Ralph Alexander ;
Karoubi, Golnaz .
BMC CANCER, 2014, 14
[9]   Multicellular resistance: a paradigm for clinical resistance? [J].
Desoize, B ;
Jardillier, JC .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2000, 36 (2-3) :193-207
[10]   Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement [J].
Dominici, M. ;
Le Blanc, K. ;
Mueller, I. ;
Slaper-Cortenbach, I. ;
Marini, F. C. ;
Krause, D. S. ;
Deans, R. J. ;
Keating, A. ;
Prockop, D. J. ;
Horwitz, E. M. .
CYTOTHERAPY, 2006, 8 (04) :315-317